-
Mashup Score: 19In Memoriam: George L. Bakris, MD (1952 to 2024) | Hypertension - 3 month(s) ago
View all available purchase options and get full access to this article. Request permissions for this article. Department of Medicine, Division of Nephrology, Richard L. Roudebush VA Medical Center, Indianapolis, IN (R.A.). Department of Medicine, University of Maryland, Baltimore (M.R.W.). Correspondence to: Rajiv Agarwal, Department of Medicine, Division of Nephrology, Richard L. Roudebush VA Medical Center, 1481 West 10th St, 111N, Indianapolis, IN 46202, Email [email protected] If you have the
Source: www.ahajournals.orgCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 18In Memoriam: George L. Bakris, MD (1952 to 2024) | Hypertension - 3 month(s) ago
View all available purchase options and get full access to this article. Request permissions for this article. Department of Medicine, Division of Nephrology, Richard L. Roudebush VA Medical Center, Indianapolis, IN (R.A.). Department of Medicine, University of Maryland, Baltimore (M.R.W.). Correspondence to: Rajiv Agarwal, Department of Medicine, Division of Nephrology, Richard L. Roudebush VA Medical Center, 1481 West 10th St, 111N, Indianapolis, IN 46202, Email [email protected] If you have the
Source: www.ahajournals.orgCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 18In Memoriam: George L. Bakris, MD (1952 to 2024) | Hypertension - 3 month(s) ago
View all available purchase options and get full access to this article. Request permissions for this article. Department of Medicine, Division of Nephrology, Richard L. Roudebush VA Medical Center, Indianapolis, IN (R.A.). Department of Medicine, University of Maryland, Baltimore (M.R.W.). Correspondence to: Rajiv Agarwal, Department of Medicine, Division of Nephrology, Richard L. Roudebush VA Medical Center, 1481 West 10th St, 111N, Indianapolis, IN 46202, Email [email protected] If you have the
Source: www.ahajournals.orgCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 18In Memoriam: George L. Bakris, MD (1952 to 2024) | Hypertension - 3 month(s) ago
View all available purchase options and get full access to this article. Request permissions for this article. Department of Medicine, Division of Nephrology, Richard L. Roudebush VA Medical Center, Indianapolis, IN (R.A.). Department of Medicine, University of Maryland, Baltimore (M.R.W.). Correspondence to: Rajiv Agarwal, Department of Medicine, Division of Nephrology, Richard L. Roudebush VA Medical Center, 1481 West 10th St, 111N, Indianapolis, IN 46202, Email [email protected] If you have the
Source: www.ahajournals.orgCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 14In Memoriam: George L. Bakris, MD (1952 to 2024) | Hypertension - 3 month(s) ago
View all available purchase options and get full access to this article. Request permissions for this article. Department of Medicine, Division of Nephrology, Richard L. Roudebush VA Medical Center, Indianapolis, IN (R.A.). Department of Medicine, University of Maryland, Baltimore (M.R.W.). Correspondence to: Rajiv Agarwal, Department of Medicine, Division of Nephrology, Richard L. Roudebush VA Medical Center, 1481 West 10th St, 111N, Indianapolis, IN 46202, Email [email protected] If you have the
Source: www.ahajournals.orgCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 461
Finerenone significantly reduced the composite of cardiovascular death and total (first and recurrent) heart failure events compared to placebo in addition to usual therapy / Approximately half of all people living with heart failure (HF) have HF with mildly reduced or preserved left ventricular ejection fraction (LVEF), i.e. a LVEF of ≥40%, h…
Source: www.bayer.comCategories: General Medicine News, CardiologistsTweet-
*Breaking* P3 #FINEARTSHF meets its primary endpoint (CVd+total HF events)! Non-steroidal MRA finerenone "demonstrates definitive CV benefits" in HFmrEF & HFpEF Looking forward to presenting full results at #ESCCongress alongside @scottdsolomon @PSJhund https://t.co/RHM58WTYbq https://t.co/PhIwUYapU7
-
-
Mashup Score: 451
Finerenone significantly reduced the composite of cardiovascular death and total (first and recurrent) heart failure events compared to placebo in addition to usual therapy / Approximately half of all people living with heart failure (HF) have HF with mildly reduced or preserved left ventricular ejection fraction (LVEF), i.e. a LVEF of ≥40%, h…
Source: www.bayer.comCategories: General Medicine News, CardiologistsTweet-
*Breaking* P3 #FINEARTSHF meets its primary endpoint (CVd+total HF events)! Non-steroidal MRA finerenone "demonstrates definitive CV benefits" in HFmrEF & HFpEF Looking forward to presenting full results at #ESCCongress alongside @scottdsolomon @PSJhund https://t.co/RHM58WTYbq https://t.co/PhIwUYapU7
-
-
Mashup Score: 449
Finerenone significantly reduced the composite of cardiovascular death and total (first and recurrent) heart failure events compared to placebo in addition to usual therapy / Approximately half of all people living with heart failure (HF) have HF with mildly reduced or preserved left ventricular ejection fraction (LVEF), i.e. a LVEF of ≥40%, h…
Source: www.bayer.comCategories: General Medicine News, CardiologistsTweet-
*Breaking* P3 #FINEARTSHF meets its primary endpoint (CVd+total HF events)! Non-steroidal MRA finerenone "demonstrates definitive CV benefits" in HFmrEF & HFpEF Looking forward to presenting full results at #ESCCongress alongside @scottdsolomon @PSJhund https://t.co/RHM58WTYbq https://t.co/PhIwUYapU7
-
-
Mashup Score: 14Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS‐HF trial - 4 month(s) ago
European Journal of Heart Failure is an ESC journal dedicated to improving the understanding, prevention, investigation and treatment of heart failure.
Source: onlinelibrary.wiley.comCategories: General Medicine News, CardiologistsTweet-
#FINEARTSHF Design Published in #EJHF Non-steroidal #MRA finerenone was specifically designed to optimize cardio-kidney protection, while mitigating risks of hyperkalemia Builds on a strong P2/3 RCT portfolio, incl comparative data versus steroidal MRAs https://t.co/uDTa7omfny https://t.co/e1ahoyHmwq
-
-
Mashup Score: 2
FINEARTS-HF met its primary endpoint, 1 achieving a statistically significant reduction of the composite of cardiovascular death and total (first and recurrent) heart failure (HF) events, defined as hospitalizations for HF or urgent HF visits 2 KERENDIA is the first non-steroidal, selective mineralocorticoid receptor antagonist (MRA) to meet a primary cardiovascular endpoint in a Phase III study investigating patients with HF with mildly reduced or preserved ejection fraction (LVEF > 40%) 1 KERENDIA already has established cardiovascular benefit (reduction in hospitalization for HF, CV death and non-fatal MI) in adults with chronic kidney disease (CKD) in type 2 diabetes (T2D) 3 , and this new topline data provides positive results in a different patient population not limited to CKD in T2D— patients diagnosed with HF (LVEF > 40) 1 The clinical data from FINEARTS-HF will be presented at the European Society of Cardiology (ESC) Congress 2024 Bayer plans to discuss the data and
Source: bayer2019tf.q4web.comCategories: General Medicine News, CardiologistsTweet
RT @AgarwalRajivMD: Matt Weir & I offer an obituary of our affable colleage George Bakris https://t.co/J7rSgdm2Fy "With a diagnosis of canc…